FOLOTYN Market Drug Insight

“FOLOTYN Market Size, Forecast, and Drug Insight – 2032” report provides comprehensive insights about FOLOTYN for Peripheral T-cell lymphoma (PTCL) in the United States, and Japan. A detailed picture of the FOLOTYN for Peripheral T-cell lymphoma (PTCL) in the United States, and Japan for the study period 2019–2032 is provided in this report along with a detailed description of the FOLOTYN for Peripheral T-cell lymphoma. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the FOLOTYN market forecast, analysis for Peripheral T-cell lymphoma in the United States and Japan, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Peripheral T-cell lymphoma.

Drug Summary

FOLOTYN (pralatrexate injection) is a dihydrofolate reductase inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). It is also a competitive inhibitor for polyglutamylation by the enzyme folylpolyglutamyl synthetase. This inhibition results in the depletion of thymidine and other biological molecules, the synthesis of which depends on single carbon transfer.

FOLOTYN is supplied as a preservative-free, sterile, isotonic, non-pyrogenic clear yellow aqueous solution contained in a clear glass single-dose vial (Type I) for intravenous use. Each 1 mL of solution contains 20 mg of pralatrexate, sufficient sodium chloride to achieve an isotonic (280–300 mOsm) solution, and sufficient sodium hydroxide and hydrochloric acid if needed to adjust and maintain the pH at 7.5–8.5. FOLOTYN is supplied as either 20 mg (1 mL) or 40 mg (2 mL) single-dose vials at a concentration of 20 mg/mL.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the FOLOTYN description, mechanism of action, dosage and administration, research and development activities in Peripheral T-cell lymphoma (PTCL).
• Elaborated details on FOLOTYN regulatory milestones and other development activities have been provided in this report.
• The report also highlights the FOLOTYN research and development activity in Peripheral T-cell lymphoma in detail across the United States, and Japan.
• The report also covers the patents information with expiry timeline around FOLOTYN.
• The report contains forecasted sales of FOLOTYN for Peripheral T-cell lymphoma till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Peripheral T-cell lymphoma.
• The report also features the SWOT analysis with analyst views for FOLOTYN in Peripheral T-cell lymphoma.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

FOLOTYN Analytical Perspective by DelveInsight

In-depth FOLOTYN Market Assessment

This report provides a detailed market assessment of FOLOTYN in Peripheral T-cell lymphoma (PTCL) in the United States, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

FOLOTYN Clinical Assessment

The report provides the clinical trials information of FOLOTYN in Peripheral T-cell lymphoma covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for Peripheral T-cell lymphoma (PTCL) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence FOLOTYN dominance.
• Other emerging products for Peripheral T-cell lymphoma are expected to give tough market competition to FOLOTYN and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of FOLOTYN in Peripheral T-cell lymphoma.
• Our in-depth analysis of the forecasted sales data from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the FOLOTYN in Peripheral T-cell lymphoma.

Key Questions

• What is the product type, route of administration and mechanism of action of FOLOTYN?
• What is the clinical trial status of the study related to FOLOTYN in Peripheral T-cell lymphoma (PTCL) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the FOLOTYN development?
• What are the key designations that have been granted to FOLOTYN for Peripheral T-cell lymphoma?
• What is the forecasted market scenario of FOLOTYN for Peripheral T-cell lymphoma?
• What are the forecasted sales of FOLOTYN in the United States, and Japan? 
• What are the other emerging products available in Peripheral T-cell lymphoma and how are they giving competition to FOLOTYN for Peripheral T-cell lymphoma?
•  
• Which are the late-stage emerging therapies under development for the treatment of Peripheral T-cell lymphoma?